Who are we? Adverse Drug Reactions Applying Theory to Clinical Practice. WS SIG-MI Barcelona October
|
|
- Godfrey Jordan
- 5 years ago
- Views:
Transcription
1 Adverse Drug Reactions Applying Theory to Clinical Practice Stephane Steurbaut, Brussels - Belgium Yolande Hanssens, Doha - Qatar ESCP Barcelona 30 October 2012 Who are we? yhanssens@hmc.org.qa y_hanssens@hotmail.com stephane.steurbaut@uzbrussel.be WS SIG-MI Barcelona October
2 3 Objectives To appreciate the importance of early recognition of possible ADRs and differentiate them from disease related events. To practice the causality scales to assist in a prompt identification of ADRs. To become familiar with information sources providing relevant details about ADRs. WS SIG-MI Barcelona October
3 Outline of this session Introduction & definitions Practical clinical guidance, sources of information & causality assessment Case studies in small groups Feedback from the groups What is happening at the European level? Current status & Conclusions ADRs - Definition Any noxious, unintended, and undesired effect of a drug that occurs at doses used in man for prevention, diagnosis, or treatment of disease, or modification of physiological function Any unwanted effect WHO, 1966 WS SIG-MI Barcelona October
4 ADRs - Terminology Adverse effect/reaction: all unwanted effects Side effect: beneficial or unwanted via same or other mechanism dose-related or not Adverse event: adverse outcome not necessarily related to drug Toxic effect: Medication error increase of the desired therapeutic effect, dose-related ADRs - Terminology I m allergic But Doctor, Pharmacist... I don t tolerate I react.... WS SIG-MI Barcelona October
5 ADRs - Classification Type A reactions: pharmacological ADR - related to the pharmacological actions of the drug - predictable, dose-related - low mortality - usually identified before drug is marketed Examples: Toxicity or overdose Secondary pharmacological effect Drug interaction ADRs - Classification Predisposing factors to type A reactions - drug formulation - drug dose - multiple drug therapy (drug-drug interactions) - gender: females >> males - age: altered pharmacokinetics altered pharmacodynamic sensitivity - underlying disease - genetic polymorphism WS SIG-MI Barcelona October
6 ADRs - Classification Type B reactions: - uncommon, unpredictable, non-dose-related, mostly NOT detected during clinical trials - not related to the pharmacological actions of the drug - high mortality Idiosyncratic reactions ADRs - Classification Comparison Type A and Type B Parameter Type A Reaction Type B Reaction Predictable Yes No Dose related Yes No Incidence High Low Frequency Regular Rare Morbidity High Low Mortality Low High Treatment Dose reduction Stop WS SIG-MI Barcelona October
7 Can I only buy the side effects of this cough syrup? ADRs - Importance account for 2-6% of all hospital admissions occur in 10-20% of hospital inpatients cause death: in 0.1% medical inpatients in 0.01% surgical inpatients Manasse HR. Am J Health Sys Pharm 1989 Lazarou J. JAMA 1998 WS SIG-MI Barcelona October
8 Terminology & overlap (1) Nebeker J.R. et al. Ann Intern Med. 2004;140: Terminology & overlap (2) Otero M.J. & Dominguez-Gil A. Farmacia Hospitalaria Med. 2000;24: WS SIG-MI Barcelona October
9 Terminology & overlap (3) Morimoto T. et al. Qual Saf Health Care. 2004;13: ADVERSE DRUG REACTIONS Importance affect patient quality of life cause patients to lose confidence in health care providers and may lead to medication non-adherence may mimic disease (unnecessary investigations and delay in treatment) increase cost of patient care BURDEN ON HEALTH CARE BUDGET WS SIG-MI Barcelona October
10 19 ADVERSE DRUG REACTIONS Diagnosis Timing dose-related reaction interacting drug previous exposure WS SIG-MI Barcelona October
11 ADVERSE DRUG REACTIONS Diagnosis pattern recognition background frequency ADVERSE DRUG REACTIONS Diagnosis 3 key questions 1. Can the drug cause the ADR? 2. Has the drug caused the ADR? 3. Will the drug cause the ADR? Also How likely is it that this drug is the cause of this problem in this specific patient? Making a differential diagnosis needs full access to all available data. WS SIG-MI Barcelona October
12 ADVERSE DRUG REACTIONS Diagnosis- Causality Challenging Discrepancies between evaluators Usage of standardized case causality assessment Algorithms and evaluation scales WHO-UMC system & Naranjo scale BUT Limitations too ADVERSE DRUG REACTIONS Advantages & limitations of standardized case causality assessment What it CAN do Decrease disagreement between assessors Classify relationship likelihood Mark individual case reports Improvement of scientific evaluations; educational What it CANNOT do Give accurate quantitative measurement of relationship likelihood Distinguish valid from invalid cases Prove the connection between drug and event Quantify the contributions of a drug to the development of an ADR Change uncertainty into certainty WS SIG-MI Barcelona October
13 WHO The Uppsala Monitoring Centre 25 WHO-UMC Causality Categories WHO-UMC WS SIG-MI Barcelona October
14 Naranjo ADR Probability Scale To assess the adverse drug reaction, please answer the following questionnaire and give the pertinent score. Yes No Do Not Know Score 1. Are there previous conclusive reports on this reaction? 2. Did the adverse event appear after the suspected drug was administered? 3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? 4. Did the adverse reactions appear when the drug was readministered? 5. Are there alternative causes (other than the drug) that could on their own have caused the reaction? 6. Did the reaction reappear when a placebo was given? 7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? 8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? 9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? 10. Was the adverse event confirmed by any objective evidence? Total Score Total Score ADR Probability Classification Naranjo CA. Clin Pharmacol Ther 1981;30: Highly Probable 5-8 Probable 1-4 Possible 0 Doubtful ADVERSE DRUG REACTIONS Diagnosis Use of Algorithm The Naranjo Algorithm 10 Questions with scoring system -1, 0, +1 and +2 Score of 9-10 definitely ADR 5-8 probable ADR 1-4 possible ADR < 1 doubtful Naranjo CA. Clin Pharmacol Ther 1981 WS SIG-MI Barcelona October
15 Outline of this session Introduction & definitions Practical clinical guidance, sources of information & causality assessment Case studies in small groups Feedback from the groups What is happening at European level? Current status & Conclusions Causality Assessment Practice in small groups Causality assessment using 1. Naranjo Scale 2. WHO-UMC system Also consider for each case Likely causes? Action to be taken? Investigations needed? Management? Further assessment? WS SIG-MI Barcelona October
16 Case 1 - Male, 56 years, 92 kg, BMI 32 - Medical conditions DM type 2 Dyslipidemia Hypertension Case 1 Current home medication Metformin 500 mg TID Atorvastatin 40 mg HS Valsartan/Amlodipine 160/5 32 WS SIG-MI Barcelona October
17 Case 1 - Admitted for minor elective surgery - Medication at Hospital Home medication + ranitidine 150 mg po BID heparin 5000 units SubQ 33 Case 1 Platelet count (normal range x10 9 /L) - Day Day Day WS SIG-MI Barcelona October
18 Case 1 Does ranitidine cause thrombocytopenia? Naranjo Score? WHO-UMC system? Action plan? 35 Ranitidine and thrombocytopenia Score? To assess the adverse drug reaction, please answer the following questionnaire and give the pertinent score. Yes No Do Not Know Score 1. Are there previous conclusive reports on this reaction? 2. Did the adverse event appear after the suspected drug was administered? 3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? 4. Did the adverse reactions appear when the drug was readministered? 5. Are there alternative causes (other than the drug) that could on their own have caused the reaction? 6. Did the reaction reappear when a placebo was given? 7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? 8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? 9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? 10. Was the adverse event confirmed by any objective evidence? Total Score Total Score ADR Probability Classification 9 Highly Probable 5-8 Probable 1-4 Possible 0 Doubtful 36 WS SIG-MI Barcelona October
19 WHO-UMC Causality for ranitidine and thrombocytopenia WHO-UMC Case 1 Are there any other reasons for thrombocytopenia in this patient? 38 WS SIG-MI Barcelona October
20 Heparin and thrombocytopenia Score? To assess the adverse drug reaction, please answer the following questionnaire and give the pertinent score. Yes No Do Not Know Score 1. Are there previous conclusive reports on this reaction? 2. Did the adverse event appear after the suspected drug was administered? 3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? 4. Did the adverse reactions appear when the drug was readministered? 5. Are there alternative causes (other than the drug) that could on their own have caused the reaction? 6. Did the reaction reappear when a placebo was given? 7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? 8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? 9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? 10. Was the adverse event confirmed by any objective evidence? Total Score Total Score ADR Probability Classification 9 Highly Probable 5-8 Probable 1-4 Possible 0 Doubtful 39 WHO-UMC Causality for heparin and thrombocytopenia WHO-UMC WS SIG-MI Barcelona October
21 Case 2, 80 years, 65 kg medical conditions: reflux gastric ulcer osteoporosis hypertension atrial fibrillation (paroxysmal) depressed Case 2 Morning Breakfast Lunch Dinner Bedtime spironolactone 50 mg bisoprolol 5 mg bisoprolol 5 mg Amlodipine 5 mg Aspirin 80 mg alendronate 70 mg (weekly) omeprazole 20 mg escitalopram 10 mg WS SIG-MI Barcelona October
22 Case 2 Hospitalisation for: decrease of general health confusion agitation sodium level: 116 meq/l Case 2 - Qs Likely causes? Action(s) to be taken? Investigations needed? Management? Further assessment? WS SIG-MI Barcelona October
23 Likely causes Case 2 - Aws Hyponatremia Drug induced? escitalopram + spironolactone Other? SIADH Case 2 - Aws Action(s) to be taken Dechallenge escitalopram (temporally) stop spironolactone? Rechallenge? WS SIG-MI Barcelona October
24 Case 2 - Aws Investigations needed Lab values electrolytes: Na, K, Blood pressure Mini-mental state Case 2 - Aws Management Infusion: 0.9% NaCl SLOWLY! 40 meq/l KCl (lab result: 3.2 meq/l) Liquid restriction WS SIG-MI Barcelona October
25 Case 2 - Aws Further assessment & follow-up Electrolyte balance Blood pressure control Assess need for antidepressive medication no (S)SRI/(S)NRI Case 4, 24 years, 85 kg, 164 cm Medical conditions: chronic: diabetes type 1 obesity hypertension acute pelvic inflammatory disease penicillin allergy WS SIG-MI Barcelona October
26 Case 4 Medication taken at home NovoRapid (insulin aspart): 8h: 30 E / 12h: 30 E / 18h: 40 E Lantus (insulin glargine): 23h: 42 E NovoRapid ramipril 8h: 5 mg Case 4 Medication received in the hospital ciprofloxacin IV 400 mg/200 ml 8h: 30 E / 12h: 30 E / 18h: 40 E paracetamol IV 1 g Complaints burning sensation erythema multiforme WS SIG-MI Barcelona October
27 Case 4 - Qs Likely causes? Action(s) to be taken? Investigations needed? Management? Further assessment? Likely causes Case 4 - Aws ADR on ciprofloxacin Preventable? penicillin allergy? infusion time: advised: 60 min here: 30 min medication error WS SIG-MI Barcelona October
28 Case 4 - Aws Action(s) to be taken Dechallenge stop ciprofloxacin IV Rechallenge? possible with correct infusion rate nevertheless, chosen to give ciprofloxacin orally Case 4 - Aws Investigations needed None Management Oral antihistaminic WS SIG-MI Barcelona October
29 Case 4 - Aws Further assessment & follow-up Erythema vanished after 45 minutes Patient recovered completely followed by hospital discharge few days later Outline of this session Introduction & definitions Practical clinical guidance, sources of information & causality assessment Case studies in small groups Feedback from the groups What is happening at the European level? Conclusions & take home messages WS SIG-MI Barcelona October
30 ADVERSE DRUG REACTIONS ADVERSE DRUG REACTIONS WS SIG-MI Barcelona October
31 ADVERSE DRUG REACTIONS ADVERSE DRUG REACTIONS WS SIG-MI Barcelona October
32 ADVERSE DRUG REACTIONS WS SIG-MI Barcelona October
33 Outline of this session Introduction & definitions Practical clinical guidance, sources of information & causality assessment Case studies in small groups Feedback from the groups What is happening at European level? Current status & Conclusions ADRs - Definition Any noxious, unintended, and undesired effect of a drug that occurs at doses used in man for prevention, diagnosis, or treatment of disease, or modification of physiological function Any unwanted effect WHO, 1966 WS SIG-MI Barcelona October
34 What triggered the WHO in 1966? 67 Softenon tragedy Thalidomide (Contergan, Softenon ) launched by Grünenthal in 1957 & marketed in 47 countries (not in US) used as samples on 20,000 US patients sold until 1961 for insomnolence & morning sickness during pregnancy 10 to 20,000 babies with deformities (phocomelia) 68 WS SIG-MI Barcelona October
35 Softenon tragedy 1 SEP 2012 apologies from Grünenthal for not trying to reach out to victims for over 50 years 5000 to 6000 sufferers are still alive Victims criticize the company for not compensating them and for ignoring the red flags Too little too late 69 Adverse Drug Reactions Applying Theory to Clinical Practice Do causality scales solve all problems? Remember What it CAN do What it CANNOT do limitations too Decrease disagreement between assessors Classify relationship likelihood Mark individual case reports Improvement of scientific evaluations; educational Give accurate quantitative measurement of relationship likelihood Distinguish valid from invalid cases Prove the connection between drug and event Quantify the contributions of a drug to the development of an ADR Change uncertainty into certainty WS SIG-MI Barcelona October
36 Method: 6 assessors 2 pharmacists 2 physicians 2 nurses - Assessed 200 ADR reports for causality using Naranjo ADR Probability Scale Venulet algorithm WHO causality term assessment criteria - Assessment of agreement between 1. assessors using the same algorithms 2. algorithms for the same assessor WS SIG-MI Barcelona October
37 Results: Majority of the causality assessments resulted in probable or possible Physician and pharmacist assessment was more likely to result in definite or certain causality assessments than nurse assessment, when using the Naranjo and WHO algorithms. Use of the Venulet algorithm resulted in a higher number of unlikely or unrelated assessments than the other two methods. Results: cont d The inter-assessor agreement measured was no greater than fair (weighted kappa = 0.31) for any comparison between raters, and for three comparisons, inter-assessor agreement was less than that expected by chance. Conversely, the weighted observed proportion of agreement, Po (w), was good (>0.6) for all assessments. Intra-assessor agreement between scales was highest for the Naranjo algorithm versus the WHO algorithm, with substantial (weighted kappa = 0.61) agreement between assessments made by pharmacist 1. The mean Po (w) for intra-assessor agreement was WS SIG-MI Barcelona October
38 Conclusions: 1. Comparability between assessors was found to be fair or less for the ADR causality assessment methods examined. 2. The most consistent results were produced by the application of the Naranjo algorithm and the least consistent was the Venulet algorithm. 3. It is likely that the clinical experience of the assessor influences how the assessment methods are applied. 4. The high level of disagreement in the results produced using the assessment scales in this study question the robustness of causality assessments. Adverse Drug Reactions Applying Theory to Clinical Practice Problems with different scales Problems of reproducibility and validity No single method is universally accepted Different causality categories are adopted in each method Categories are assessed using different criteria Assessment methods are also not entirely devoid of individual judgments, therefore inter-rater reliability can be low In conclusion, there is still no method universally accepted for causality assessment of ADRs Agbabiaka TB, Drug Saf. 2008;31(1): WS SIG-MI Barcelona October
39 Adverse Drug Reactions Applying Theory to Clinical Practice So, what did we do this afternoon? BUT with the growing rate of new pharmaceuticals Early recognition of potential ADRs is critical Reporting of ADRs is an essential part of healthcare practice We cannot allow another Softenon tragedy ADRs Useful Websites & References WS SIG-MI Barcelona October
40 WS SIG-MI Barcelona October
TITLE: SAFE USE OF MEDICINES IN ZANZIBAR A
Table of content Acknowledgements Introduction TITLE: SAFE USE OF MEDICINES IN ZANZIBAR A guide for health professionals in detecting and reporting adverse drug reaction. (Beautiful photograph tablets
More information2. Adverse Drug Reactions
2. Adverse Drug Reactions Background Medicines Information Centres receive many enquiries specifically about adverse drug reactions (ADRs), as well as a large number featuring related patient safety issues
More informationADVERSE DRUG REACTION REPORTS IN MALAYSIA: COMPARISON OF CAUSALITY ASSESSMENTS
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 7 17 (2007) ADVERSE DRUG REACTION REPORTS IN MALAYSIA: COMPARISON OF CAUSALITY ASSESSMENTS HOE SEE LEI 1*, AB FATAH AB RAHMAN 1 AND ABIDA HAQ
More informationPHARMACOVIGILANCE: WHEN ADVERSE DRUG EVENTS OCCUR. Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP
PHARMACOVIGILANCE: WHEN ADVERSE DRUG EVENTS OCCUR Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP Disclosure Information PHARMACOVIGILANCE Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz,
More informationdrug reactions A method for estimating the probability of adverse
A method for estimating the probability of adverse drug reactions The estimation of the probability that a drug caused an adverse clinical event is usually based on clinical judgment. Lack of a method
More informationAdverse Drug Reactions (ADRs) Outline
Adverse Drug Reactions (ADRs) Outline 1. What are Adverse Drug Reactions (ADRs)? WHAT WHY HOW 2. How important are ADRs and are they preventable? 3. What are the classifications and mechanisms of ADRs?
More informationPHARMACY INTERVENTION RECORD FORM 1.7 Medicine
Date / /20 Pharmacist initials Ward Patient Demographics (as Hospital Number) Point Admissions (A) Care of the Elderly(CE) Respiratory (R) Gastroenterology(G) Rheumatology (Rh) Endocrine (E) Other (o)
More informationPHARMACOVIGILANCE GLOSSARY
PHARMACOVIGILANCE GLOSSARY Section 1 Section 2 Section 3 Section 4 Definitions of terminology used for side effects Definitions of drug safety terms Definitions of risk terminology Definitions of general
More informationPractical Medicines Management
Practical Medicines Management Linda Bryant/Fiona Corbin/Leanne Te Karu Pharmac Seminar Series Medicines in Healthcare August 2015 Even people who have access to drugs may not receive the right medicine
More informationWho are we? Drug dosing in special patient populations. Zamzam Ahmed, London United Kingdom Yolande Hanssens, Doha - Qatar
Drug dosing in special patient populations Zamzam Ahmed, London United Kingdom Yolande Hanssens, Doha - Qatar ESCP Prague 16 October 2013 Who are we? yhanssens@hmc.org.qa y_hanssens@hotmail.com zamzam.ahmed.11@ucl.ac.uk
More informationA study of adverse reaction algorithms in a drug surveillance program
A study of adverse reaction algorithms in a drug surveillance program To improve agreement among observers, several investigators have recently proposed methods (algorithms) to standardize assessments
More informationGuideline for Children with Type 1 or Type 2 Diabetes on Insulin Requiring Surgery or Sedation
CHILDREN S SERVICES Guideline for Children with Type 1 or Type 2 Diabetes on Insulin Requiring Surgery or Sedation Background Surgery places stress on the body and will alter glucose control and insulin
More informationAppendix A: Sample Patient Profiles and Prescriptions
Appendix A: Sample Patient Profiles and Prescriptions (For Pharmacist Use) Sample Patient Profile 1 Name Mike Monroe Date of Birth 01/01/1957 Address 555 Happy Lane Phone 123-456-7890 Tucson, AZ 85704
More informationDisclosure. Screening for adverse drug events: a tool to improve safe medication use
Screening for adverse drug events: a tool to improve safe medication use John T. Holmes, PharmD, BCPS Assistant Professor Departments of Family Medicine and Pharmacy Practice Idaho State University Disclosure
More informationAdverse Experience Reporting
Managing and reporting adverse events Key learning objectives By the end of this session, you will be able to: Define and classify an adverse event; Differentiate between serious and severe adverse events;
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationDiabetes, Ketone testing in Type 1 Diabetes
CLINICAL GUIDELINE Diabetes, Ketone testing in Type 1 Diabetes A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationPolypharmacy & De-prescribing In Older Adults
Polypharmacy & De-prescribing In Older Adults Maryland Association of Osteopathic Physicians Annual Meeting September 15, 2018 Elizabeth Phung, DO Lead Clinical Associate Physician Beacham Center for Geriatric
More informationAdverse Drug Reactions Year 2 Clinical Pharmacology
1 Adverse Drug Reactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2018 2 Objectives Explain how to predict, identify and characterise an adverse
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationInterprofessional Outpatient Clinic Polypharmacy Management. Objectives
Interprofessional Outpatient Clinic Polypharmacy Management Brett Hoffecker, MD University of Kansas School of Medicine Wichita Family Medicine Residency Program at Via Christi April 10th, 2015 Objectives
More informationA Process for Performing Medication Assessments
A Process for Performing Medication Assessments Derek Jorgenson, BSP, PharmD, FCSHP College of Pharmacy and Nutrition University of Saskatchewan Objectives 1. Learn an overview of a medication assessment
More informationSAE håndtering i protokol CC MM-001
SAE håndtering i protokol CC-92480-MM-001 An SAE is any AE occurring at any dose that: Results in death; Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate risk of
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationGeriatric Pharmacology
Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological
More informationInsulin Initiation, titration & Insulin switch in the Primary Care-KISS
Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationTransitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018
Transitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018 Objectives Identify when to complete medication reconciliation Understand the importance
More informationReason for referral: provide patient education on management of hypoglycemia and glucose monitor
Meet Robin Sawyer (otherwise known as PT 1): Let s Create a Care Plan! Reason for referral: provide patient education on management of hypoglycemia and glucose monitor History of present illness: 40 45
More informationMedicines for high blood pressure
Patient Information: Medicines Medicines for high blood pressure Health & care information you can trust The Information Standard Certified Member Working together for better patient information What is
More informationSafe use of insulin regular concentrated (500 units/ml) in severe insulin resistance
Safe use of insulin regular concentrated (500 units/ml) in severe insulin resistance Jodie S. Gee, Pharm.D., BCACP, CDE Clinical Pharmacy Specialist-Ambulatory Care Harris Health System Objectives To be
More informationSample. Fractured Hip Post-Operative Orders. Legend < Mandatory fields o Optional fields. Height Allergies: List or o Up to date in electronic system
Legend Mandatory fields o Optional fields Height Allergies: List or o Up to date in electronic system cm Weight Diagnosis kg Date (yyyy-mon-dd) Time (hh:mm) Anticipated Date Of Discharge (ADOD) o Greater
More informationTopic: Chronic Heart Failure Cases for Monday s March 21th lecture.
1 Phar6122: CV section Date: 3/10/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In
More informationAllergy Status Identification And Documentation
Allergy Status Identification And Documentation Basic Medication Safety (BMS) Certification Course King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs Learning
More informationComplete this CE activity online at ProCE.com/InsulinPart2
Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationDEPRESCRIBING IN THE ELDERLY
DEPRESCRIBING IN THE ELDERLY G E R I A T R I C S R E F R E S H E R D A Y W E D N E S D A Y, A P R I L 5 TH, 2 0 1 7 V É R O N I Q U E F R E N C H M E R K L E Y, M D, C C F P ( C O E ) B R U Y È R E C O
More informationDetermination of Incidence and Characteristics of Preventable Adverse Drug Reactions : A Study in Phrae Hospital
55 Determination of Incidence and Characteristics of Preventable Adverse Drug Reactions : A Study in Phrae Hospital Kannika Thiankhanithikun* and Sayam Kaewvichit Faculty of Pharmacy, Chiang Mai University,
More informationAdverse drug reactions. Prof. dr. Jolanta Gulbinovič
Adverse drug reactions Prof. dr. Jolanta Gulbinovič Definitions Adverse event Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not
More informationLet it go! Rationalising medicines for patients with life limiting illness
Let it go! Rationalising medicines for patients with life limiting illness Inga Andrew Senior Clinical Pharmacist Northumbria Healthcare Trust E-mail: inga_andrew@northumbria-healthcare.nhs.uk Welcome
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationSerious Adverse Event (SAE) Form Clinical Trials
Protocol Code number: LP0162-1334 1. Trial information: Subject ID: Site No.: Country: Is this the initial report of an SAE or a follow-up? Initial Follow-up, follow up no. In which period of the trial
More informationGlycemic Control Insulin In The Hospital Setting
Glycemic Control Insulin In The Hospital Setting Glycemic Control The Evidence For Insulin s s Benefit The Mechanism of Insulin s s Benefit The Achievement of Insulin s s Benefit A Few Cases Hyperglycemia
More informationIt Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia
It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia Jacqueline LaManna, PhD, ANP BC, BC ADM, CDE Holly Divine, PharmD, BCACP, CGP, CDE, FAPhA Disclosures Dr. Jacqueline LaManna
More informationCase #3 Clinician. Past Medical History: hypertension, hypercholesterolemia, arthritis, seasonal allergies, remote history of stroke
Case #3 Clinician Be the clinician taking a best possible medication history Use the space below to document your best possible medication history You are going to see patient Frank Ribello Reason for
More information100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hedussin syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L.,
More informationHave participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).
Blood Pressure Management and Control Protocol BP Management: A) BP goal: Achieve blood pressure values less than 130/80mmHg. B) Process: Have participants measure their blood pressure daily at a standard
More informationAdverse Drug Reactions pattern in a tertiary level teaching hospital: A Retrospective Study
Original Article Adverse Drug Reactions pattern in a tertiary level teaching hospital: A Retrospective Study Anita Gupta, Anjleen Kaur, Prashant Shukla*, Hema Chhabra Department of Pharmacology, Government
More informationCARDIAC REHABILITATION PROGRAMME:- MEDICATION
CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to
More informationEvaluation of Clinical Text Segmentation to Facilitate Cohort Retrieval
Evaluation of Clinical Text Segmentation to Facilitate Cohort Retrieval Enhanced Cohort Identification and Retrieval S105 Tracy Edinger, ND, MS Oregon Health & Science University Twitter: #AMIA2017 Co-Authors
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI SHINE Synopsis Acute ischemic stroke
More informationMyeloma Haematology and Transplant Unit CTD1
CTD1 Myeloma Haematology and Transplant Unit CTD1 This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of
More informationThe Importance of Reporting Adverse Drug Reactions and Creating a Culture of Safety. Kristy Malacos Magruder Hospital Pharmacy Systems, Inc.
The Importance of Reporting Adverse Drug Reactions and Creating a Culture of Safety Kristy Malacos Magruder Hospital Pharmacy Systems, Inc. Objectives Describe Adverse Drug Reactions (ADR)and the importance
More informationPathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
More informationBasic Principles in Pharmacology
L. 1 Dr. Mohammed AL-Zobaidy Basic Principles in Pharmacology Learning objectives: by the end of this lecture you should Understand the possible uses of drugs. Explain why a drug has different names. Identify
More informationStudy setup: Medicine units of tertiary care teaching hospital
3. Methodology 3.1. Development of indicators for identifying ADEs 3.1.1. Study Period: November 2007- April 2008 3.1.2. Study setup: Medicine units of tertiary care teaching hospital 3.1.3. Development
More informationPolypharmacy. Polypharmacy. Suboptimal Prescribing in Older Adults. Kenneth Schmader, MD Professor of Medicine-Geriatrics
Polypharmacy Kenneth Schmader, MD Professor of Medicine-Geriatrics Polypharmacy Definition Causes Consequences Prevention/management Suboptimal Prescribing in Older Adults Overuse Polypharmacy Underuse
More informationEnhanced Recovery After Surgery (ERAS) Diary
Cardiac Surgery Enhanced Recovery After Surgery (ERAS) Diary Patient s Name: Options available If you d like a large print, audio, Braille or a translated version of this leaflet then please call: 01253
More informationPharmaceutical Care for Geriatrics
Continuing Professional Pharmacy Development Program Pharmaceutical Care for Geriatrics Presented by: Alla El-Awaisi; MPharm, MRPharmS, MSc Event Organizer: Dr. Nadir Kheir; PhD Disclaimer: PRESENTING
More informationCase 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?
Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationPRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER
PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER BEFORE STARTING YOUR PATIENTS ON SOLIRIS Important safety information for the healthcare provider Prior to initiating
More informationSerious Adverse Event (SAE) Form Clinical Trials
Protocol Code number: LP0162-1325 1. Trial information: Subject ID: Site No.: Country: If blinded trial, was the study treatment unblinded? Yes No Is this the initial report of an SAE or a follow-up? Initial
More informationNES Asthma Hospital Medication Care Plan 7
NES Asthma Hospital Medication Care Plan 7 PATIENT DETAILS Name Liz Duncan Address Consultant Gender Female Weight 60kg Height 1.6m General Practitioner Dr Jones Community Pharmacist Date of Birth (Age)
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationCLINICAL ANALYSIS OF ADVERSE DRUG REACTIONS. Christine Chamberlain, Pharm.D., BCPS, CDE FDA, CDER, OSE, Division of Pharmacovigilance
CLINICAL ANALYSIS OF ADVERSE DRUG REACTIONS Christine Chamberlain, Pharm.D., BCPS, CDE FDA, CDER, OSE, Division of Pharmacovigilance February 2015 2 Disclaimer The views in this presentation on clinical
More informationTamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali
10 Tamer Barakat Abdul Aziz ALShamali Abdul Aziz ALShamali Dr. Alia Elimination: Refampin is used to treat TB not malaria (Quinacrine is used for malaria) It s the opposite process of absorption. It's
More informationEvaluating Effectiveness of Treatments. Elenore Judy B. Uy, M.D.
Evaluating Effectiveness of Treatments Elenore Judy B. Uy, M.D. OUTLINE 1. Why evaluate effectiveness 2. How to acquire evidence 3. How to appraise evidence Directness Validity Results 4. Our Case WALA
More informationNHS Greater Glasgow And Clyde Pain Management Service. Information for Adult Patients who are Prescribed. Duloxetine. For the Treatment of Pain
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Duloxetine For the Treatment of Pain This information is not intended to replace your doctor s advice.
More informationMANAGEMENT OF DIABETES IN PREGNANCY
MANAGEMENT OF DIABETES IN PREGNANCY Ministry of Health Malaysia Malaysian Endocrine & Metabolic Society Perinatal Society of Malaysia Family Medicine Specialists Association of Malaysia Academy of Medicine
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationFrom medicines reconciliation to medicines review. Dr. Fatma Karapinar Hospital pharmacistepidemiologist
From medicines reconciliation to medicines review Dr. Fatma Karapinar Hospital pharmacistepidemiologist Conflict of interest Nothing to disclose Questions Medication review is more important than medicines
More informationFairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45
Fairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45 1. Your diabetic patient is to be started on an insulin drip at 8 units/hour. The insulin is supplied: 100 units in
More informationCHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female
More informationCarbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8
PHA 5128 Dose Optimization II, Spring 2013, Case Study IV Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationSCENARIO 1: ICD-10-CM
ICD-10 Tobacco Billing Guide Scenarios SCENARIO 1: 16-year-old male Sports physical examination and annual check-up Shortness of breath upon exertion Smokes 5-6 cigarettes a day Began smoking 8 months
More informationEND OF LIFE CARE FOR THE FRAIL ELDERLY
Intensive Care Unit END OF LIFE CARE FOR THE FRAIL ELDERLY Ken Hillman Interface of Palliative Care and ICU/Critical Care. Palliative Care South Australia. 19 March 2018. Adelaide. THE CHALLENGE Increasing
More informationEmpowering Older Adults On Drug Adherence A Collaborative Service Model. Cheng Po-po, Peggy Nurse Consultant (Gerontology) Yan Chai Hospital, KWC, HA
Empowering Older Adults On Drug Adherence A Collaborative Service Model Cheng Po-po, Peggy Nurse Consultant (Gerontology) Yan Chai Hospital, KWC, HA Introduction Older adults have multiple pathologies
More informationACE. Inhibitors. Quiz feedback
ACE Inhibitors Quiz feedback bpac nz better medicin e bpac nz Quiz feedback, ACE inhibitors, 2006 Best Practice Advocacy Centre ACE inhibitors quiz feedback bpac nz Development Team: Rachael Clarke Sonia
More informationMyeloma Haematology and Transplant Unit MPT
MPT Myeloma Haematology and Transplant Unit MPT This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Joyce Robson Learning Outcomes Think about the place of injectible therapies in diabetes Think about when / why patients require insulin therapy
More informationKey Elements in Adverse Drug Interaction Safety Signals
Drug Saf (2013) 36:63 70 DOI 10.1007/s40264-012-0003-9 ORIGINAL RESEARCH ARTICLE Key Elements in Adverse Drug Interaction Safety Signals An Assessment of Individual Case Safety Reports Johanna Strandell
More informationHigh Alert Medications in the long-term care setting. Carrie Allen PharmD, CGP, BCPS, CCHP
High Alert Medications in the long-term care setting Carrie Allen PharmD, CGP, BCPS, CCHP Who does this involve? Nurses Medication aides Pharmacies/pharmacists Medical Records and Data Entry Personnel
More informationMyeloma Haematology and Transplant Unit
BCD Myeloma Haematology and Transplant Unit BCD This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationPRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA
PRESCRIPTION PAD The Newsletter of the Cumbria Area Prescribing Committee February 2012 No. 18 Click here to find more Clinical policy and Formulary news Lothian changes Targeted Medication Use Reviews
More informationDear Clinicians, We welcome you to us your stories directly at or click "Reply" to this . Thank you!
Dear Clinicians, We have received questions from several clinicians regarding what to do when encountering a patient with a high blood pressure alert or diabetic emergency at a health fair. Attached you
More informationIncidence and Severity of Adverse Drug Reactions and Spontaneous Adverse Drug Reporting in Hospital Settings of Lahore
International Journal of Scientific and Research Publications, Volume 7, Issue 5, May 2017 655 Incidence and Severity of Adverse Drug Reactions and Spontaneous Adverse Drug Reporting in Hospital Settings
More informationCHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS
CHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS 1. The following is an accurate description of the aging population: A. The number of older adults will reach 17 million in 2030 B. The ratio of women to
More informationConcentrated Insulin & Patient Management THE QUALITY CENTER PATIENT SAFETY ORGANIZATION FEBRUARY 27, 2018
Concentrated Insulin & Patient Management THE QUALITY CENTER PATIENT SAFETY ORGANIZATION FEBRUARY 27, 2018 1 Today s Agenda 1. Introduction to concentrated insulin 2. Best practices for management of concentrated
More informationDKA Adult ICU Powerplan
DKA Adult ICU Powerplan Key Points for ED to ICU DKA power plan In addition to NS fluids and maintenance the regular insulin drip will either already be infusing from ED or needs to be initiated. Regular
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationDiagnosis and Management of UTI s in Care Home Settings. To Dip or Not to Dip?
Diagnosis and Management of UTI s in Care Home Settings To Dip or Not to Dip? 1 Key Summary Points: Treat the patient NOT the urine In people 65 years, asymptomatic bacteriuria is common. Treating does
More informationDON T LET OBESITY SPOIL YOUR HEALTH AND YOUR LIFE
July 2015 Issue No.17 DON T LET OBESITY SPOIL YOUR HEALTH AND YOUR LIFE www.sghgroup.com JEDDAH RIYADH MEDINA ASEER HAIL SANAA DUBAI CAIRO Definitions Over View and General Facts General Key facts! Worldwide
More informationImproving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies
Improving Inpatient Diabetes Care: Focus on Safe Use of Anti-diabetic Therapies Leigh Briscoe-Dwyer, PharmD, BCPS, FASHP Chief Pharmacy and Medication Safety Officer North Shore Long Island Jewish Health
More information